Through the design and development of our personalized cell-therapy platform, Minovia is on a journey of discovery to improve and extend people’s lives.
Minovia’s mitochondrial process is a platform, that will be applied to other mitochondrial disorders including KSS, LHON, MELAS, anticipating X# INDs by end of 2020.
Our strategy is to focus on and establish proof-of-concept in rare mitochondrial diseases with no approved therapy and with limited numbers of drugs under clinical development. Two such diseases are Pearson Syndrome which affects about 100 patients worldwide, and Kearns-Sayre Syndrome (KSS) which affects around 7,000 patients across the US, EU and Japan.
Indications by end of 2020